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Abstract
Antibodies against HIV-1 proteins in HIV-1-infected individuals share a cross-reactive idiotype defined by the monoclonal antiidiotypic antibody 1F7 (5). Using a computer
algorithm based on the molecular recognition theory, regions of inverse hydropathy between the variable sequence
of 1F7 and human monoclonal anti-HIV-1 antibodies were
identified, which are assumed to be involved in idiotypeantiidiotype contacts. A peptide was designed from the proposed contact in the variable heavy chain framework 3complementarity determining region 3 (FR3-CDR3) of human antibodies and was synthesized. This peptide is recognized by the antiidiotype 1F7 and inhibits the binding of
1F7 to human anti-HIV-1 antibodies which express the 1F7
idiotype. A survey of normal and HIV-1-infected sera revealed the presence of antibodies in infected sera which
bind to the FR3-CDR3 peptide. The biological relevance of
autoantibodies against a self idiotope associated with HIV1 infection is discussed in the context of the regulation of
the antibody response to HIV-1. (J. Clin. Invest. 1995.
96:775-780.) Key words: HIV-1 * AIDS * autoantibody
idiotype * peptide

Introduction
The function of idiotypic networks has been discovered in a
large number of experimental immune responses as well as in
diseases (for review see reference 1). In several of these immune responses, idiotypes and antiidiotypes have been used to
manipulate or induce immunities (for review see reference 2).
A general obstacle in the idiotype network approach is the
imprecise knowledge of idiotypic structures on immunoglobulins and T cell receptors. Recently, a new method has been used
to identify the molecular contacts between (CDRs)' of idiotype
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and antiidiotypes (3). This approach is based on hydropathic
complementarity, the so-called molecular recognition theory,
which predicts the sequence regions involved in protein-protein
interactions (4). This theory allows one to search protein sequences using a known ligand for regions which have inverse
hydropathies and thus the potential for binding to the ligand
probe. When applied to antiidiotypic antibodies, one can search
for idiotope target region in the respective idiotypic immunoglobulins.
We have used this method (3) and searched for inverse
hydropathies in human anti-HIV-1 antibodies for regions
which are recognized by a murine monoclonal antiidiotypic
antibody which reacts with a shared AIDS disease-specific idiotope (5, 6). This antibody, called 1F7, "sees" an idiotope
expressed by human antibodies against HIV-1-encoded proteins and is only detected in individuals infected with HIV-1.
For this study, the VH and VL cDNAs of 1F7 were cloned and
sequenced. The sequence region predicted by inverse hydropathy for interaction with the variable regions of 1F7 are in the
FR3-CDR3 regions of heavy chains of lF7-positive human antiHIV antibodies (7). Here we show that in sera of infected
individuals antibodies exist which bind to a peptide derived
from the heavy FR3/CDR3 region of human anti-HIV-1 antibodies predicted as idiotypic target for the 1F7 antiidiotype
mAb.

Methods
Sequence determination of the exon for IF7 VH and VL Total RNA was
isolated from 1 x 107 1F7 hybridoma cells by the procedure described
by Chomczynski and Sacchi (8). mRNA was prepared by passage
through two cycles of chromatography on oligothymidylate-cellulose
columns (9). First strand cDNA was synthesized using SuperScript
Preamplification kit (GIBCO/BRL, Gaithersburg, MD). The DNA fragment encoding the VH of 1F7 was then amplified by PCR using the 5'primer GGGAATFCATGRAATGSASCTGGGTYWTYCTCTf and
the 3 '-primer CCCAAGCTTCCAGGGRCCARKGGATARACIGRTGG (I = inosine, R = A or G, Y = C or T, K = G or T, S = C or
G, W = A or T) corresponding to sequences of the leader (signal
peptide) region, amino acids from -20 to -13, and the it constant
region, amino acids 126-119. In addition, the 5'-primer contains the
EcoRI site and the 3 '-primer contains a HindIll site, providing an alternative cloning strategy (Novagen, Inc., Madison, WI). To minimize the
error rates in PCR amplification, pfu DNA polymerase (Stratagene,
Inc., San Diego, CA) was used for amplification. Mutant frequency with
this thermostable DNA polymerase is '/1o compared with Taq DNA
polymerase. The fragment of cDNA amplified was subcloned into pT7
plasmid and NovaBlue competent cells were transformed using a protocol provided by the supplier (Novagen Inc.). Plasmid DNA was prepared by miniprep procedure (9) and the DNA sequence of the doublestranded plasmid was determined by Sequenase Version 2.0 kit (U.S.B.
Biologicals, Cleveland, OH). The sequence of the DNA insert in the
plasmid was determined from both orientations using T7 promoter
primer (TAATACGACTCACTATAGGG) and U-19 primer (GTT-
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Figure 1. Translated amino acid sequence of VL (a) and VH (b). IdB5.7
VH is aligned with 1F7 VH and M-T30 Vk with 1F7 Vk showing highest
homologies with 1F7 chains. Underlined residues indicate amino acid
differences.

TTCCCAGTCACGACGT). At least three clones were picked for sequence determination. The sequence of the 1F7 light chain was similarly
determined.
Peptides. Peptide 422(LRSVDTAIYYCARL), 436(QLTSVKAVDTAIYYCARL), and control peptide 291 (CYSKNQRNESSHGGE) were synthesized on a 431A Peptide Synthesizer (ABI Advanced
Riotechnologies, Inc., Columbia, MD) utilizing FMOC chemistry. p436
contains NH2-terminal additional sequence derived from 71-31 mAb;
p291 is derived from the calmodulin-binding domain of rat plasma
membrane Ca2' ATPase isoform 3.
Peptide-binding ELISA. Plates were coated with 100-il peptides at
concentration of 10 ag/ml, overnight at 4°C. After blocking at room
temperature for 1 h, 1F7 at 0, 20, 40, 60, 80, and 100 ,ug/ml or 0, 0.01,
0.1, 1, and 10 jig/ml were added and incubated at 37°C for 2 h. After
washing, peroxidase-labeled goat anti-mouse IgM-horseradish peroxidase (HRP) (1:1,000 dilution) (Southern Biotechnology Associates,
Birmingham, AL) was used and left at room temperature for 1.5 h. After
washing as above, enzyme activity was revealed by o-phenylendiamine
dihydrochloride substrate (Sigma Chemical Co., St. Louis, MO) reading
at 490 nm. Alternatively, human sera, 1:1,000 diluted, were added to
peptide-coated plates. After washing 1:1,000 diluted goat anti-human
IgG-HRP was added and ELISA was developed as above.
Id inhibition assay. To determine the idiotype specificity of rabbit
anti-p422 sera, rabbit anti-p422 sera was added to p422-coated plates
together with 1F7 (IgM, K) or TEPC 183 (IgM, K) at different concentrations at 37°C for 2 h. ELISA was developed with goat anti-rabbit
HRP. Similarly, HIV+ sera, 1:800 diluted, was added together with
1F7 or TEPC 183 to p422-coated plates and ELISA was developed
with goat anti-human Ig HPR (1:1,000 diluted). Inhibition rate was
calculated using the equation:
% inhibition

=

100 x

(1

Absorbance with inhibitor

Absorbance without inhibitor

(1)

Biotinylation ofp422 and IF7-binding assays. NHS-LC-Biotin was
linked to p422 utilizing a commercial kit (Pierce Chemical Co., Rockford, IL). To measure the binding ability of biotinylated-p422 to 1F7,
plates were coated with 1F7 at 2 Ag/ml overnight at 4°C. Free sites
were blocked at room temperature for 1 h. Biotinylated-p422 was added
and incubated at 37°C for 2 h. Bound p422 was visualized by streptavidin-HRP (Southern Biotechnology Associates) and o-phenylendiamine
dihydrochloride.
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Figure 2. Schematic representation of predicted interaction between
CDRs and FRs of the 1F7 antiidiotype antibody and VH regions of three
human anti-HIV-l antibodies. The open boxes are CDRs from VL and
VH of 1F7, the closed boxes are CDRs from the VH of 257-D, 268-D,
and 71-31. Arrows indicate complementary contacts. Regions with double lines and letters indicate IDR (14).

Rabbit anti-p422 antibodies. Rabbits were immunized with keyhole
limpet hemocyanin-conjugated peptide, 100 jig in CFA and IFA. After
the 4th immunization the sera were tested. Rabbit serum was added to
p422-coated plates and binding was detected by goat anti-IgG HRP
(Southern Biotechnology Associates). Inhibition of rabbit sera binding
by human HIV+ sera was done by coincubation with rabbit anti-p422
sera. Inhibition of binding was calculated as described above.
Human sera. Serum samples from 30 asymptomatic HIV-1-infected
individuals were purchased from North American Biologicals Inc., (Miami, FL). Serum samples from 25 HIV-1-infected individuals with
confirmed clinical status of AIDS were obtained from Dr. Michael
McGrath, UCSF, San Francisco, California. Plasma specimens and serum of babies perinatally infected with HIV-1 of PI and P2 status were
obtained from Dr. Savita Pahwa, North Shore University Hospital, Manhasset, New York, and Dr. P. A. Tovo, University of Turino, Turino,
Italy.

Results
Cloning and DNA sequencing of VH and VL of IF7 antiidiotype
antibody. The genes coding for the variable heavy and light
chain domains of the 1F7 antibody were cloned using VH and
VL-specific primers. The nucleic acid sequence of the cDNA
clones were determined using standard methods (see Methods).
The translated sequence of the variable regions of heavy and
light chain are shown in Fig. 1, a and b. Computer homology
search of the Kabat data bank (10) indicated homologies for
the heavy chain of 1F7 with an anti-Id antibody against a (16) Dextran antibody ( 11 ) and for the light chain with an antiCD4 antibody M-T380 (12).
Identification of idiotypic contact regions for IF7 and design of idiotope target peptide for 1F7. Regions of inverted
hydropathy were searched for between the 1F7 antiidiotypic
antibody and several human anti-HIV-1 antibodies to identify
potential contact sites between the 1F7 and anti-HIV-1 antibodies (3). The hydropathic profiles of the 1F7 VL and VH were
compared to the hydropathic profiles of the anti-gpl2O (MN)
mAbs, 268-D and 257-D, the anti-p24 mAb 71-31 and the antigp4l mAb 98-6 (7). Previously, we have found that these three

Dedsm of 1F7 Idotope Peptde
id AnUgefRl)

71-31

DR3
VH
Sa)NWc2)

LRSV.DT.A.LXYYCAGV

257-D

LKASDTALXYY

268-D

V T A A D S A Lx Y Y C

p422

LRSVDTAxYYCARL

ies, i.e., antiidiotypic antibodies. Such sites have been previously described by us in generic terms as idiotope determining
regions (IDR) on the basis of surface variability plots (13, 14).
A complementary idiotype target peptide for the 1F7 was
designed based on the IDRs of 257-D, 268-D, and 71-32 consisting of 14 amino acids. The peptide and its parental origin
are shown in Fig. 3. This peptide is called p422.
Binding of 1F7 to idiotope target peptide p422. To demonstrate that the 14 mer p422 peptide is the target for the antiidiotypic 1F7 mAb we tested the binding of 1F7 to p422. ELISA

Figure 3. Design of 1F7
idiotope peptide. The
CDR and FR regions of
three 1F7-positive antibodies are shown. The
underlined sequences

RL.
Z

were used to design the
p422 peptide.

human mAbs, 268-D, 257-D, and 71-31 bind to 1F7, i.e., are
1F7 Id positive (6). The hydropathic profile of a running window of at least six amino acids from 1F7 were scanned against
the human anti-HIV-1 antibody sequences. 1F7 was also
scanned against itself as control. The sequences were scanned
in both directions. The indicated potential contact sites between
1F7 and its 1F7 Id-positive anti-HIV-1 antibodies are indicated schematically in Fig. 2.
Five regions from 1F7 match with five regions of the Id
antibodies, most of which are at or near CDRs (Fig. 2). One
hit occurs with 257-D, which overlaps with one of the hits from
268-D, and two hits occur with 71-31, both of which are in the
framework 3 (FR3) of 71-31. The three mAbs, which are 1F7
positive, display hits with the CDR regions of 1F7. In contrast,
the 1F7 negative 98-6 mAb indicates complementary sites only
in the in FR regions. Interestingly, 1F7 when scanned against
itself, reveals a hit at FR2-L2 and H2. Since these two chains
of 1F7 must associate to form a functional immunoglobulin
molecule, it is not unexpected that some complementarity is
displayed. The regions of complementarity that are presented
on the surface of the Ig molecule, such as those at or near the
CDRs, are expected to represent contact sites for other antibod1F7

plates were coated with different amounts of p422 peptide or
control peptides, p291 and p436. After washing, coated plates
were incubated with 1F7 at different concentrations and bound
1F7 (IgM, K) was detected with peroxidase-labeled goat antimouse IgM. As seen in Fig. 4 a, 1F7 bound to p422-coated
plates in concentration-dependent fashion and did not bind to
the control peptide p291, or to p436 (Fig. 4, b and c. An
unrelated mouse IgM, TEPC 183, was used as control in binding
to p422-coated plates (Fig. 4 d).
The p422-1F7 interaction was also demonstrated by reversing the ELISA configuration. Plates were coated with 1F7
and incubated with dilutions of biotin-conjugated p422 peptide.
As seen in Fig. 5 a, increasing concentrations of biotinylated
p422 peptide added to IF7-coated plates produced increasing
ELISA reading with enzyme-labeled avidin. Next, the specificity of p422 binding to 1F7 was tested by inhibition experiments.
As shown in Fig. 5 b, the binding of 1F7 to 1F7 Id-positive
antibodies in HIV-positive serum is inhibited dose dependently
by p422 but not by the control peptide p291.
Collectively these data demonstrate that the 1F7 antiidiotype
mAb binds to a peptide derived from the sequences of human
mAbs which express the 1F7 idiotope. This also supports the
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Figure 4. (a) Binding of 1F7 to
p422-coated plates. Plates were
coated with increasing amounts of
p422 peptides and different concentrations of 1F7 were added.
After washing ELISA was developed with goat enzyme-labeled
anti-mouse IgM. (b and c) Binding of 1F7 to control peptides
p291 and p436 using identical
ELISA. (d) Binding of TEPC 183
to p422-coated plates. ELISA as
in a.
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utility of the inverse hydropathy relationship in protein-protein
interaction as a method to search for sequences involved in
protein binding.
To further confirm that the p422 peptide expresses the idiotope target for the 1F7 antiidiotype mAb, a polyclonal antibody
against p422 was produced in rabbits. Rabbit anti-p422 serum
binds to p422 coated plates (Fig. 6 a), but does not bind to
control peptide p291-coated plates. If p422 is the 1F7 idiotope
or a major part of this idiotope, the binding of rabbit anti-p422 to
p422 should be inhibited by 1F7. As seen in Fig. 6 b, increasing
amounts of 1F7 produced strong inhibition of p422 binding,
while the unrelated mouse IgM TEPC 183 did not inhibit binding. These results demonstrate that the p422 peptide contains
antigenic structures recognized by both the mouse monoclonal
and the rabbit polyclonal antibody thereby confirming the idiotopic antigenicity of the p422 sequence.
Binding of serum antibodies from HPV-I -infected individuals to the 1F7 idiotopic peptide p422. 1F7 binds to a shared
idiotope on anti-HIV-1 antibodies with different specificities
(5,6) and is only found in HIV-1 -infected individuals. Because
of this broad reactivity and association with HIV infection, it
is conceivable that the 1F7 idiotope is also the target for selfrecognition in infected individuals; in other words, autoantibodies might exist in seropositive individuals which recognize the
1F7 idiotope.
Sera from 51 HIV-1-infected individuals were tested for
binding to p422-coated plates in ELISA. Fig. 7 a shows a representative ELISA with one HIV+ serum in which anti-p422
activity is detectable. The binding is dilution dependent for both
p422 and serum. A pool of sera from uninfected individuals
shows no binding to p422 (Fig. 7 b). No binding is detected
with the HIV+ serum to the control peptide (Fig. 7 c). The
specificity of binding to p422 was tested by using the 1F7
antibody as competitor for HIV+ serum. As seen in Fig. 7 d,
1F7, but not the control IgM TEPC 183, competes with HIV+
serum for binding to p422 peptide.
Finally, the possibility that the binding of serum antibodies
to 1F7 may be nonspecific and unrelated to the p422 idiotypic
peptide was excluded by showing that only the binding to 1F7
778
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Figure 6. (a) Binding of rabbit anti-p422 serum to p422-coated plates.
p422-coated plates were incubated with dilutions of rabbit antisera and
ELISA was developed using enzyme-labeled goat anti-rabbit IgG. Sera
were also added to p291-coated plates as control. (b) Inhibition of
binding of rabbit anti-p422 sera to p422 by 1F7 and TEPC 183. Dilutions
of rabbit sera were coincubated with different amounts of 1F7 or TEPC
183 and added to p422-coated plates.

can be inhibited by p422 and that the background binding to
a control murine IgM, TEPC 183, is not affected by p422

(Fig. 8).
Since not all HIV-l -infected individuals produce 1F7 reactive antibodies, (- 70% are 1F7 positive [5, 6]), it was of
interest to ask whether the expression of 1F7 Id and autoantiId are associated or not. Serum samples from IF7-positive and
IF7-negative individuals were assayed for binding to p422 peptide. As seen in Table I, 31 out of 51 1F7+ sera also contained
anti-p422 antibodies; none of 4 1F7 Id-negative HIV seropositive sera react with p422. No binding to p422 was seen in nonHIV-1 infected IF7-Id-negative seroreverting babies (Table I)
and in seronegative sera from 20 adult HIV-seronegative blood
donors (data not shown). We also tested sera from infected
babies and found that 22/27 IF7-positive sera contained antibodies to p422 (Table I).
These results show that the autoantiidiotypic, i.e., IF7-like,
activity is correlated with the expression of the corresponding
1F7 idiotype.

Discussion
In this report we describe a peptide which is recognized by
antibodies in sera from HIV-1-infected individuals. This pep-
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Figure 8. Inhibition of HIV+ serum antibody binding to 1F7 or TEPC
183 by p422. Plates were coated with goat anti-IgM, 1F7 (IgM, K), or
TEPC 183 (IgM, K) were added together with increasing amount of
p422; IF7+ serum was added and ELISA was developed with goat
anti-human IgG-HRP.

Figure 7. (a) Binding of human
HIV-1 + serum to p422. Serial dilutions of serum from an HIV- 1infected individual were added to
p422-coated plates. Binding antibodies were detected using enzyme-labeled goat anti-human
IgG. (b) Absence of binding of
normal human serum to p422. (c)
Absence of binding of human
HIV-1 + serum to p291. (d) Inhibition of binding of human HIV1+ serum to p422 by 1F7 and
TEPC 183. Human HIV-1+ serum (1:800 diluted) was added in
presence of increasing amounts of
I1F7 to p422-coated plates ( 10 sg/
plate).

CDR3 regions of heavy chains of the human anti-HIV-1 antibodies.
The molecular recognition theory (4) has been used previously to generate antiidiotypic antibodies against autoantibodies and antibodies against hormones and receptors (for review
see reference 3). This approach was used here to identify contacts between monoclonal idiotype and antiidiotype antibodies.
This system is of considerable interest since the shared 1F7
idiotype is involved in cytotoxic effector function (Grant, M.,
M. Gomez, and F. Smail, unpublished data) and as target for
enhancing apoptosis of T cells from infected individuals
(Muller, S., P. Brams, and H. Collins, unpublished data). The
hydropathy analysis predicted the CDR regions which are involved in contacts between 1F7 and the human anti-HIV-1
antibodies. While the idiotope target region for 1F7 could be
mimicked by a peptide, peptides synthesized from 1F7 (antiId) CDRs failed to bind to anti-HIV-1 antibodies (data not
shown). This suggests that the binding site of the 1F7 antiId is composed of more than one CDR arranged in a threedimensional configuration, a model, compatible with our current

Table L
tide was designed from the sequence of human monoclonal
antibodies against the viral envelope proteins gpl20 and gp4l,
which react with a monoclonal antiidiotypic antibody recognizing a shared idiotope in sera of HIV-1-infected individuals
(6). A search for inverse hydropathies (3, 4) between the monoclonal antiidiotypic antibody and human antienvelope antibodies indicated potential idiotope contacts which provided the
sequence information for the peptide design. The sequence region used for the synthesis of the peptide comes from the FR3/

No. of
1F7 Id+

No. of anti-p422

Sera

(anti-Id)

Percent Id+
and anti-Id+

HIV-1+ adult*
HIV-1 + babiest

51
27

31
22

62
81.5

* None of 4 HIV-1 + 1F7 Id negative sera was anti-P422 (anti-Id
positive). * None of 25 1F7 negative, sero-reverting baby sera was antiP422 (anti-Id) positive.
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understanding of antibody structure. In contrast, the idiotope
target (idiotype seen by 1F7) appears to consist predominantly
of a linear region which covers sequences from the framework
and CDR. The combined involvement of framework together
with hypervariable regions has been predicted by our previously
described IDR model (14).
In the strictest sense these antipeptide antibodies are not
autoantibodies since the peptides used were not derived from
anti-HIV in sera studied here. However, because 1F7 binds to
monoclonal human anti-HIV antibodies (6), which provided
the sequence data for designing the p422 peptide, the human
antipeptide antibodies are homologous autoantibodies. Therefore, we are using the term autoantibodies in this report.
The autoantibodies against a self IDR described here in
sera from HIV-infected individuals are the second example of
autoantibodies against a linear, peptide-defined, variable immunoglobulin epitope. Previously (15) we have identified another
IDR consisting of CDR2-FR3 VH sequences recognized by antibodies in sera of certain mouse strains and of humans. This
IDR is part of the murine germ line gene S107 Vl. In mice
antibodies against phosphorylcholine, the dominant epitope of
C-polysaccharide, utilize the VI germ line gene. While autoantibodies against CDR2-FR3 of S 107 VI recognize a nonmutated
IDR, the antibodies against the p422 IDR peptide, described
here, react with an IDR generated in part by somatic mutational
and selective events. This is not unexpected since the infection
with HIV- 1 in evolution is a recent event not allowing for
coselection of germ line-encoded IDRs. The 1F7 IDR described by the p422 peptide, is quite unique as it is not present
on the 1F7 Id-negative human monoclonal anti-HIV-1 antibody 98-6 (6) and because a computer search of the sequence
data bank ( 10) did not identify other antibodies with an identical
sequence in this VH location except the IDR expressing 71-31
VH (7). The generation of the p422 IDR by somatic and selective processes is further supported by the finding that this IDR
is found on antibodies belonging to different VH gene families
(16). On the other hand, the sequence of the 1F7 antiidiotypic
antibody has high homologies in both chains with two other
antibodies directed against members of the Ig superfamily, an
anti-Id (11) and an anti-CD4 (12), respectively, see Fig. 1.
The reasons why the humoral immune response to HIV
antigens selects for antibodies expressing the 1F7 IDR are unclear, but the participation of this epitope as described in several
HIV infection-related immunological systems (6, 16; Grant,
M., M. Gomez, and F. Smail, unpublished data; Miller, S., P.
Brams, and H. Collins, unpublished data) suggests a biological
activity of the 1F7 like autoantibodies in sera of infected individuals.
The murine 1F7 monoclonal antiidiotypic antibody reacts
with anti-HIV-1 antibodies of different specificities (5, 6). 1F7
Id has been detected in all stages of HIV-1 infection (5; Grant,
M., M. Gomez, and F. Smail, unpublished data), as well as in
serum from gpl20/160 vaccine volunteers and also in sera of
experimentally HIV-1-IIIB-infected chimpanzees (17). 1F7
has also been shown to play a role in cytotoxic T lymphocyte
activity as it suppresses cytotoxicity in vitro (Grant, M., M.
Gomez, and F. Smail, unpublished data).
Collectively, the data on 1F7 reactivity with antibodies and
T cells in HIV-l -infected individuals shows that this idiotype
is involved in the immune response to HIV-1 infection. The
finding of an autoantiidiotypic humoral response against the
780
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1F7 idiotype, reported here, adds further evidence for a biological role of 1F7 in AIDS. The significance of identifying the
molecular target for 1F7 as a CDR-FR peptide lies in the
potential to manipulate the immune response to HIV infection
using peptide-based vaccines. What exactly the role of 1F7-like
antibodies is remains subject to speculation at this time, and
this question requires further studies.

Acknowledgments
We thank Marcia Ballard for help in preparation of the manuscript and
Mike Russ, University of Kentucky Macromolecular Structure Analysis
Facility, for synthesis of peptide p422, purification, amino acid analysis,
and technical advice.
The work was supported by NIH grants NS 29719 to J. Edwin
Blalock and CA 56701 to Heinz Kohler and American Foundation for
AIDS Research grant number 500281-14-PG to Sybille Muller.

References
1. Bona, C. A., and H. Kohler. 1983. Immune Networks. Ann. NYAcad. Sci.
418:
2. Kohler, H., S. Kaveri, T. Kieber Emmons, J. W. Morrow, S. Miller, and
S. Raychaudhuri. 1989. Idiotypic Networks and Nature of Molecular Mimicry:
an Overview. Methods Enzymol. 178:1-36.
3. Maier, C. C., H. N. B. Moseley, S.-R. Zhou, J. N. Whitaker, and J. E.
Blalock. 1994. Identification of interactive determinants on idiotypic-anti-idiotypic antibodies through comparison of their hydropathic profiles. Complementary
Peptides: Application in Immunology and as Antibody Mimetics. ImmunoMethods. 5:107-113.
4. Blalock, J. E. 1990. Complementarity of peptides specified by "sense"
and "antisense" strands of DNA. Trends in Biotechnol. 8:140-144.
5. Muller, S., H.-T. Wang, S. Kaveri, S. Chattopadhyay, and H. Kdhler. 1991.
Generation and specificity of monoclonal anti-idiotypic antibodies against human
HIV-specific antibodies. J. Immunol. 147:933-941.
6. Wang, H.-T., S. Muller, S. Zolla-Pazner, and H. Kohler. 1992. Human
Anti-HIV antibodies with different epitope specificity share common clonotypic
markers. Eur. J. Immunol. 22:1749-1755.
7. Andris, J. S., S. Johnson, S. Zolla-Pazner, and D. Capra. 1991. Molecular
characterization of five human anti-human immunodeficiency virus type 1 antibody heavy chains reveals extensive somatic mutation typical of an antigen-driven
immune response. Proc. Natl. Acad. Sci. USA. 88:7783-7787.
8. Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA isolation
by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem.
162:156-159.
9. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular Cloning: A
laboratory Manual, 2nd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor,
New York.
10. Kabat, E. A., T. T. Wu, H. M. Perry, K. S. Gottesman, and C. Foeller.
1991. Sequences of proteins of immunological interest. 5th ed. U.S. Department
of Health and Human Services.
11. Perfetti, V., P. Borden, M.-M. Tao, S. L. Morrison, and E. A. Kabat.
1991. Specificity and variable region cDNA sequence of an isogeneic monoclonal
antiidiotype to an anti-alpha (1-6) dextran. Mol. Immunol. 28:505-515.
12. Weissenhorn, W., W. Scheuer, B. Kaluza, M. Schwirzke, C. Reiter, D.
Flieger, H. Lenz, E. H. Weiss, E. P. Rieber, G. Riethmueller, and U. H. Weidle.
1992. Combinatorial functions of two chimeric antibodies directed to human CD4
and one directed to the alpha-chain of the human interleukin-2 receptor. Gene.
121:271-278.
13. Kieber-Emmons, T., and H. Kohler. 1986. Evolutionary origin of autoreactive determinants. Proc. Natl. Acad. Sci. USA. 83:2521-2525.
14. Kieber-Emmons, T., and H. Kohler. 1986. Towards a unified theory of
immunoglobulin structure-function relations. Immunol. Rev. 90:29-48.
15. Kaveri, S., C-Y. Kang, and H. Kohler. 1990. Natural mouse and human
antibodies bind to a peptide derived from a germline variable heavy chain: evidence for evolutionary conserved self-binding locus. J. Immunol. 145:4207-4213.
16. Muller, S., H.-T. Wang, G. Silverman, G. Bramlet, N. Haigwood, and H.
Kohler. 1993. B-cell abnormalities in AIDS: stable and clonally-restricted antibody response in HIV-1 infection. Scand. J. Immunol. 38:327-334.
17. Muller, S., D. Schwartz, H.-T. Wang, Q. Wang, H. Kohler, S. Pahwa,
P.-A. Tovo, and P. Nara. 1995. Expression of an HIV-1 infection related idiotype/
clonotype in antibodies directed to envelope glycoprotein gpl20 of HIV-1: early
and concomitant idiotype increase in antibodies against the homologous vaccine
strain. Vaccine Res. In press.

